Follow-up strategies and management of recurrence in urologic oncology bladder cancer: Invasive bladder cancer

Urologic Clinics of North America

Volumn 30, Issue 4, 2003, Pages 777-789

  Bochner, Bernard H ^a   Montie, James E ^b   Lee, Cheryl T ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYANOCOBALAMIN; DOCETAXEL; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; PACLITAXEL; VINBLASTINE;

BLADDER CANCER; BLADDER NECK; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; COLOSTOMY; COMPUTER ASSISTED TOMOGRAPHY; CYSTECTOMY; CYTOLOGY; ELECTROLYTE DISTURBANCE; ENDOSCOPY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INTRAVENOUS PYELOGRAPHY; INVASIVE CARCINOMA; LAPAROSCOPIC SURGERY; MALABSORPTION; MEGALOBLASTIC ANEMIA; METABOLIC ACIDOSIS; METABOLIC DISORDER; METASTASIS; NEPHROURETERECTOMY; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; PELVIS LYMPH NODE; PELVIS LYMPHADENECTOMY; PLASTIC SURGERY; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE COMPLICATION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; RECURRENCE RISK; RETROGRADE PYELOGRAPHY; REVIEW; SIDE EFFECT; SURGICAL TECHNIQUE; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; TUMOR BIOPSY; URETERECTOMY; URINARY DIVERSION; UROGENITAL TRACT TUMOR; UROLITHIASIS;

EID: 0344442753     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-0143(03)00061-2     Document Type: Review

References (94)

1. Smith JA Jr, Batata M, Grabstald H, Sogani PC, Herr H, Whitmore WF Jr. Preoperative irradiation and cystectomy for bladder cancer. Cancer 1982;49(5):869-73.
2. Whitmore WF, Marshall V. Radical surgery for carcinoma of the urinary bladder. Cancer 1956;9:596-8.
3. Montie JE. Follow-up after cystectomy for carcinoma of the bladder. Urol Clin North Am 1994;21(4):639-43.
4. Schoenberg MP, Walsh PC, Breazeale DR, Marshall FF, Mostwin JL, Brendler CB. Local recurrence and survival following nerve sparing radical cystoprostatectomy for bladder cancer: 10-year followup [comment]. J Urol 1996;155(2):490-4.
5. Skinner DG, Lieskovsky G. Contemporary cystectomy with pelvic node dissection compared to preoperative radiation therapy plus cystectomy in management of invasive bladder cancer. J Urol 1984;131(6)1069-72.
6. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001;19(3):666-75.
7. Greven KM, Spera JA, Solin LJ, Morgan T, Hanks GE. Local recurrence after cystectomy alone for bladder carcinoma. Cancer 1992;69(11):2767-70.
8. Pisters LL, Westney L. The management of locally recurrent invasive bladder cancer following radical cystectomy. Semin Urol Oncol 1996;14(2):112-9.
9. Wishnow KI, Dmochowski R. Pelvic recurrence after radical cystectomy without preoperative radiation. J Urol 1988;140:42-3.
10. Herr HW, Bochner BH, Dalbagni G, Donat SM, Reuter VE, Bajorin DF. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol 2002;167(3): 1295-8.
11. Leissner J, Hohenfellner R, Thuroff JW, Wolf HK. Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis. BJU Int 2000;85(7):817-23.
12. Poulsen AL, Horn T, Steven K. Radical cystectomy: extending the limits of pelvic lymph node dissection improves survival for patients with bladder cancer confined to the bladder wall. J Urol 1998;160(6 Pt 1):2015-9.
13. Kaplan SA, Sawczuk IS, O'Toole KM, Olsson CA. Contemporary cystectomy versus preoperative radiation plus cystectomy for bladder cancer. Urology 1988;32:485-91.
14. Montie JE, Straffon RA, Stewart BH. Radical cystectomy without radiation therapy for carcinoma of the bladder. J Urol 1984;131(3):477-82.
15. Roehrborn CG, Sagalowsky AI, Peters PC. Long-term patient survival after cystectomy for regional metastatic transitional cell carcinoma of the bladder. J Urol 1991;146(1):36-9.
16. Westney OL, Pisters LL, Pettaway CA, Tu SM, Pollack A, Dinney CP. Presentation, methods of diagnosis and therapy for pelvic recurrence following radical cystectomy for transitional cell carcinoma of the bladder. J Urol 1998;159(3):792-5.
17. Dalbagni G, Genega E, Hashibe M, et al. Cystectomy for bladder cancer: a contemporary series. J Urol 2001;165(4):1111-6.
18. Frazier HA, Robertson JE, Dodge RK, Paulson DF. The value of pathologic factors in predicting cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. Cancer 1993;71(12): 3993-4001.
19. Ghoneim MA, el-Mekresh MM, el-Baz MA, el-Attar IA, Ashamallah A. Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases. J Urol 1997;158(2):393-9.
20. Pagano F, Bassi P, Galetti TP, et al. Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification. J Urol 1991;145(1):45-50.
21. Jewett HJ, Strong G. Infiltrating carcinoma of the bladder: relation to depth of penetration of the bladder wall to incidence of local extension and metastasis. J Urol 1946;55:366-8.
22. Loehrer P, Einhorn L, Elson P, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a Cooperative Group Study. J Clin Oncol 1992;10:1066-72.
23. Moore M, Tannock I, Ernst D, Huan S, Murray N. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 1997;15:3441-5.
24. Pollera C, Ceribelli A, Crecco M, Calabresi F. Weekly gemcitabine in advanced bladder cancer: a preliminary report. Ann Oncol 1994;5:132-4.
25. Stadler W, Kuzel T, Roth B, Raghavan D, Dorr F, Phase II. study of single-agent gemcitabine in previously treated patients with metastatic urothelial cancer. J Clin Oncol 1997;15:3394-8.
26. Roth B, Dreicer R, Einhorn L, et al. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 1994;12:2264-70.
27. McCaffrey J, Hilton S, Mazumdar M, et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 1997;15:1853-7.
28. Witte R, Elson P, Bono B, et al. Eastern Cooperative Oncology Group Phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol 1997;15:589-93.
29. Bajorin D, McCaffrey J, Hilton S, et al. Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial. J Clin Oncol 1998;16:2722-7.
30. Kaufman D, Raghavan D, Carducci M, et al. Phase II trial of gemcitabine and cisplatin for metastatic urothelial cancer. J Clin Oncol 2000;18:1921-7.
31. Von der Maase H, Hansen S, Roberts J, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;17:3068.
32. Sternberg C, Yagoda A, Scher H, et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 1989;64:2448-58.
33. Saxman S, Propert K, Einhorn L, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 1997;15:2564-9.
34. Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999;17:3173-81.
35. Geller N, Sternberg C, Penenberg D, et al. Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. Cancer 1991;67:1525-31.
36. Graeber G, Gupta N, Murray G. Positron emission tomographic imaging with fluorodeoxyglucose is efficacious in evaluating maligant pulmonary disease. J Thorac Cardiovasc Surg 1999;117:719-7.
37. Ogunbiyi OA, Flanagan FL, Dehdashti F, et al. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol 1997;4:613-20.
38. Balaji K, McGuire M, Grotas J, Grimaldi G, Russo P. Upper tract recurrences following radical cystectomy: an analysis of prognostic factors, recurrence pattern and stage at presentation. J Urol 1999;162:1603-6.
39. Kentworthy P, Tanguay S, Dinney C. The risk of upper tract recurrence following cystectomy in patients with transitional cell carcinoma involving the distal ureter. J Urol 1996;155:501-3.
40. Malkowicz SB, Skinner DG. Development of upper tract carcinoma after cystectomy for bladder carcinoma. Urology 1990;36(1):20-2.
41. Slaton JW, Swanson DA, Grossman HB, Dinney CP. A stage specific approach to tumor surveillance after radical cystectomy for transitional cell carcinoma of the bladder. J Urol 1999;162(3 Pt 1):710-4.
42. Stenzl A, Bartsch G, Rogatsch H. The remnant urothelium after reconstructive bladder surgery. Eur Urol 2002;41:124-31.
43. Studer U, Zingg E. Ileal orthotopic bladder substitutes: what we have learned from 12 years' experience with 200 patients. Urol Clin North Am 1997;24:781-93.
44. Yossepowitch O, Dalbagni G, Golijanin D, et al. Orthotopic urinary diversion after cystectomy for bladder cancer: implications for cancer control and patterns of disease recurrence. J Urol 2003;169:177-81.
45. Zincke H, Garbeff P, Beahrs J. Upper urinary tract transitional cell cancer after radical cystectomy for bladder cancer. J Urol 1984;131:50-2.
46. Braslis K, Soloway M. Management of ureteral and renal pelvic recurrence after cystectomy. Urol Clin North Am 1994;21:653-9.
47. Schellhammer P, Whitmore WJ. Transitional cell carcinoma of the urethra in men having cystectomy for bladder cancer. J Urol 1976;115:56-60.
48. El-Gabry E, Strup S, Gomella L. Superficial bladder cancer: epidemiology, diagnosis, and natural history. AUA Update Series 2000;19:145-52.
49. Heaney M, Francis I, Cohan R, et al. Orthotopic neobladder reconstruction: findings on excretory urography and CT. Am J Roentgenol 1999;172:1213-20.
50. Chen G, El-Gabry E, Bagley D. Surveillance of upper urinary tract transitional cell carcinoma: the role of ureteroscopy, retrograde pyelography, cytology and urinalysis. J Urol 2000;164:1901-4.
51. Hall M, Womack S, Sagalowsky A, Carmody T, Erickstad M, Roehrborn C. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 1998;52:594-601.
52. Held P, Brunner F, Odaka M, et al. Five-year survival for end-stage renal disease patients in the United States, Europe, and Japan: 1982 to 1987. Am J Kidney Dis 1990;15:451.
53. Jabbour M, Smith A. Primary percutaneous approach to upper urinary tract transitional cell carcinoma. Urol Clin North Am 2000;27:739-50.
54. Assimos D, Hall M, Martin J. Ureteroscopic management of patients with upper tract transitional cell carcinoma. Urol Clin North Am 2000;27:751-60.
55. Thalmann G, Markwalder R, Walter B, Studer U. Long-term experience with bacillus Calmette-Guérin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery. J Urol 2002;168:1381-5.
56. Zincke H, Neves R. Feasibility of conservative surgery for transitional cell carcinoma of the upper urinary tract. Urol Clin North Am 1984;11:717.
57. Gill I, Sung G, Hobart M, et al. Laparoscopic radical nephroureterectomy for upper tract transitional cell carcinoma: the Cleveland Clinic experience. J Urol 2000;164:1513-22.
58. Lerner S, Blute M, Richardson R, Zincke H. Platinum-based chemotherapy for advanced transitional cell carcinoma of the upper urinary tract. Mayo Clin Proc 1996;71:945-50.
59. Beahrs J, Fleming T, Zincke H. Risk of local urethral recurrence after radical cystectomy for bladder cancer. J Urol 1984;131:264-6.
60. Raz S, Mclorie G, Johnson S, Skinner DG. Management of the urethra in patients undergoing radical cystectomy for bladder carcinoma. J Urol 1978;120:298-300.
61. Tobisu K, Tanaka Y, Mizutani T, Kakizoe T. Transitional cell carcinoma of the urethra in men following cystectomy for bladder cancer: multivariate analysis for risk factors. J Urol 1991;146:1551-4.
62. Tongaokar H, Dalal A, Kulkarni J, Kamat M. Urethral recurrences following radical cystectomy for invasive transitional cell carcinoma of the bladder. Br J Urol 1993;72:910-4.
63. Freeman J, Tarter T, Esrig D, et al. Urethral recurrence in patients with orthotopic ileal neobladders. J Urol 1996;156:1615-9.
64. Hardeman S, Soloway M. Urethral recurrence following radical cystectomy. J Urol 1990;144:666-9.
65. Levinson K, Johnson D, Wishnow K. Indications for urethrectomy in an era of continent urinary diversion. J Urol 1990;144:73-5.
66. Stein P, Cote R, Freeman J, et al. Indications for lower urinary tract reconstruction in women after cystectomy for bladder cancer: a pathological review of female cystectomy specimens. J Urol 1995;154:1329-33.
67. Stenzl A, Draxl H, Posch B, Colleselli K, Falk M, Bartsch G. The risk of urethral tumors in female bladder cancer: can the urethra be used for orthotopic reconstruction of the lower urinary tract? J Urol 1995;153(3 Pt 2):950-5.
68. Stein J, Esrig D, Freeman J, et al. Prospective pathologic analysis of female cystectomy specimens: risk factors for orthotopic diversion in women. Urology 1998;51:951.
69. Lebret T, Herve JM, Barre P, et al. Urethral recurrence of transitional cell carcinoma of the bladder. Predictive value of preoperative lateromontanal biopsies and urethral frozen sections during prostatocystectomy. Eur Urol 1998;33(2): 170-4.
70. Cresswell J, Roberts J, Neal D. Urethral recurrence after radical radiotherapy for bladder cancer. J Urol 2001;165:1135-7.
71. Hickey D, Soloway M, Murphy W. Selective urethrectomy following cystoprostatectomy for bladder cancer. J Urol 1986;136:828.
72. Lin D, Herr H, Dalbagni G. Value of urethral wash cytology in the retained male urethra after radical cystoprostatectomy. J Urol 2003;169:961-3.
73. Tefilli M, Gheiler E, Tiguert R, et al. Urinary diversion-related outcome in patients with pelvic recurrence after radical cystectomy for bladder cancer. Urology 1999;53:999-1004.
74. McDougal W. Metabolic complications of urinary diversion. J Urol 1992;147:1199.
75. Schmidt J, Hawtrey C, Flocks R, Culp D. Complications, results and problems of ileal conduit diversion. J Urol 1973;109:210.
76. Madersbacher S, Schmidt J, Eberle J, et al. Long-term outcome of ileal conduit diversion. J Urol 2003;169:985-90.
77. Poulsen A, Steven K. Acid-base metabolism following bladder substitution with the ileal urethral Kock reservoir. Br J Urol 1996;78:47.
78. Filipsson S, Hulten L, Lindstedt G. Malabsorption of fat and vitamin B12 before and after intestinal resection for Crohn's disease. Scand J Gastroenterol 1978;13:529.
79. Thompson W, Wrathell E. The relation between ileal resection and vitamin B12 absorption. Can J Surg 1977;20:461.
80. Akerlund S, Delin K, Kock N, Lycke G, Philipson B, Volkmann R. Renal function and upper urinary tract configuration following urinary diversion to the continent ileal reservoir (Kock pouch): a prospective 5 to 11 year follow-up after reservoir construction. J Urol 1989;142:964.
81. Stein R, Lotz J, Andreas J, et al. Long-term metabolic effects in patients with urinary diversion. World J Urol 1998;16:292-7.
82. Weise E, Fleischmann A, Studer U. Persistent hypertriglyceridaemia in patients after construction of a low pressure ileal orthotopic reservoir. J Urol 1997;157:238.
83. Gerharz E, Köhl U, Weingärtner K, Melekos M, Bonfig R, Riedmiller H. Complications related to different continence mechanisms in ileocecal reservoirs. 1997:158:1709-13.
84. Kristjansson A, Mansson W. Refluxing or non-refluxing ureteric anastomosis. BJU Int 1995;84:905.
85. Studer UE, Danuser H, Thalmann GN, Springer J, Turner W. Antireflux nipples or afferent tubular segments in 70 patients with ileal low pressure bladder substitutes: long-term results of a prospective randomized trial. J Urol 1996;156:1913.
86. Elmajian DA, Stein JP, Skinner DG. Orthotopic urinary diversion: the Kock ileal neobladder. World J Urol 1996;14(1):40-6.
87. Hautmann RE. The ileal neobladder. Atlas Urol Clin North Am 2001;9:85.
88. Pantuck A, Han K, Perrotti M, Weiss R, Cummings K. Ureteroenteric anastomosis in continent urinary diversion: long-term results and complications of direct versus nonrefluxing techniques. J Urol 2000;163:450.
89. Johnson D, Oke E, Dunnick N, et al. Percutaneous ballon dilatation of ureteral strictures. Am J Roentgenol 1987;148:181-4.
90. Bierkens A, Oosterhof G, Meuleman E, et al. Anterograde percutaneous treatment of ureterointestinal strictures following urinary diversion. Eur Urol 1996;30:363-8.
91. Shapiro MJ, Banner MP, Amendola MA, et al. Balloon catheter dilation of ureteroenteric strictures: long-term results. Radiology 1988;168:385-7.
92. Meretyk S, Clayman R, Koavoussi L, et al. Endourological treatment of ureteroenteric anastomotic strictures: long-term follow up. J Urol 1991;145:723-7.
93. Cornud F, Lefebvre J, Chretien Y, et al. Percutaneous transrenal electro-incision of ureterointestinal anastomotic strictures: long-term results and comparison of fluoroscopic and endoscopic guidance. J Urol 1996;155:1575-8.
94. DiMarco D, LeRoy A, Thieling S, Bergstralh E, Segura J. Long-term results of treatment for ureteroenteric strictures. Urology 2001;58:909-13.